Friday Pop Quiz 11/8/2024
The patient developed this cutaneous adverse event 2 weeks after starting a clinical trial medication. What is the mechanism of action of the culprit medication?
A. Epidermal growth factor receptor (EGFR) inhibitor
B. Tumor necrosis factor (TNF)-alpha inhibitor
C. Smoothened inhibitor
D. BRAF inhibitor
E. Programmed cell death (PD)-1 inhibitor
To find out the correct answer and …
The patient developed this cutaneous adverse event 2 weeks after starting a clinical trial medication. What is the mechanism of action of the culprit medication?
A. Epidermal growth factor receptor (EGFR) inhibitor
B. Tumor necrosis factor (TNF)-alpha inhibitor
C. Smoothened inhibitor
D. BRAF inhibitor
E. Programmed cell death (PD)-1 inhibitor
To find out the correct answer and … 
This condition can occur as a side effect of which of the following?
A. Cetuximab
B. Methotrexate
C. Vemurafenib
D. 5-Fluorouracil
E. Bleomycin
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner Derm In-Review. A product of SanovaWorks.
… 
The patient developed this cutaneous adverse event 2 weeks after starting a clinical trial medication. What is the mechanism of action of the culprit medication?
A. Epidermal growth factor receptor (EGFR) inhibitor
B. Tumor necrosis factor (TNF)-alpha inhibitor
C. Smoothened inhibitor
D. BRAF inhibitor
E. Programmed cell death (PD)-1 inhibitor
To find out the correct answer and … 
The patient developed this cutaneous adverse reaction 2 weeks after starting a clinical trial medication. What is the mechanism of action of the culprit medication?
A). Epidermal growth factor receptor (EGFR) inhibitor
B.) Tumor necrosis factor (TNF)-alpha inhibitor
C.) Smoothened inhibitor
D.) BRAF inhibitor
E.) Programmed cell death (PD)-1 inhibitor
To find out the correct answer a … 